As the mechanism of action between monoclonal antibodies and CAR T cells is known to be quite different, it is necessary to explore the anti-tumor activities of CLDN18.2 CAR-T in gastrointestinal (GI) cancer. The gene discussed is CLDN18; the disease is neoplasm.